Treatment with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at post-treatment week 12, which was superior to the prior efficacy threshold.
Lana Pine
Advertisement
Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Articles by Lana Pine
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
2
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
3
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
4
DOOR Analysis Shows Antibiotic Matches Standard Therapy in Effectiveness
5
